The Colony Count Illusion: A Pharmacist's Checklist for Probiotics That Reach the Gut Alive

The Number on the Front Is Not the Number That Arrives

A probiotic label is a promise made on the day of manufacture. The consumer, however, buys the product months later, stores it in a warm kitchen cabinet, swallows it on an empty stomach, and expects the figure on the front of the bottle to describe what reaches the small intestine. In most cases, it does not. That gap — between the printed colony-forming unit count and the number of viable organisms that survive the journey — is one of the least discussed issues in the supplement aisle, and one of the most consequential for anyone treating a probiotic as though it were a drug.

Probiotics in the United States are regulated as dietary supplements under the Dietary Supplement Health and Education Act of 1996. They are not approved by the Food and Drug Administration for the treatment or prevention of any disease, and manufacturers are not required to demonstrate that a finished product delivers the labeled dose at the end of its shelf life. The label is a declaration of intent, not a certificate of potency. Understanding that distinction is the first step toward evaluating these products sensibly.

What CFU Actually Measures

Colony-forming units are a laboratory estimate of living microbes capable of reproducing under specific conditions. A stated count of 50 billion CFU means that, when the manufacturer performed its assay, roughly that many organisms in the sample formed colonies on a culture plate. It says nothing about which strains were counted, whether the assay was performed at release or at expiry, or how the product behaved after weeks of temperature fluctuation in a delivery truck.

Three labeling conventions dominate the market, and they are not equivalent:

• Count at time of manufacture. The figure was accurate when the batch was released. By the expiry date, viability may have fallen substantially, particularly for freeze-dried Lactobacillus and Bifidobacterium species.
• Count guaranteed through expiry. The manufacturer commits to the stated figure at the end of shelf life, which typically requires an overage at release. This is the more meaningful claim, but only when the guarantee is stated explicitly on the package rather than implied in marketing copy.
• Count of a blend. A single headline number may combine dozens of strains, some present in trivial amounts. A product listing twenty strains and 50 billion CFU may deliver less than one billion CFU of any individual strain.

Pharmacy staff should look for a specific, verifiable statement — "guaranteed through expiration" or "potency verified at expiry" — rather than a bare number.

Strain Identity Matters More Than the Total

Microbiology is specific. Lactobacillus rhamnosus GG is not interchangeable with an uncharacterized Lactobacillus rhamnosus, and neither is interchangeable with Saccharomyces boulardii, a yeast with a distinct clinical literature. Genus and species names alone are insufficient; the strain designation is the level at which evidence is generated.

Consumers frequently ask which probiotic is "best." The honest answer is that the question cannot be answered without a target. Products studied for antibiotic-associated diarrhea, for irritable bowel syndrome, and for infant colic involve different organisms at different doses. A product with a large total count but no characterized strains offers no way to connect it to any body of evidence.

Formulation: What the Capsule Does and Does Not Do

Survival through the stomach is a formulation problem as much as a microbiological one. Gastric acid, bile salts, and digestive enzymes reduce viability for many vegetative organisms. Manufacturers respond with several strategies:

• Enteric coating. Designed to resist gastric acid and release in the intestine. Effectiveness depends on the coating's integrity, and a capsule that has been stored in humid conditions may not perform as intended.
• Spore-forming organisms. Species such as Bacillus coagulans survive in a dormant state and tolerate heat and acid far better than vegetative Lactobacillus. Their durability is genuine, though the clinical literature is smaller.
• Yeast-based products. Saccharomyces boulardii is intrinsically resistant to gastric acid, which is one reason it appears in travel and antibiotic-associated diarrhea products.
• Oily suspensions and blister packs. These can protect against moisture but add cost and bulk.

A product with a modest count and appropriate formulation may deliver more viable organisms than a product advertising a hundred billion CFU in an unprotected powder.

Storage Is Part of the Dose

Viability declines with heat, humidity, and time. A shelf-stable product that has been stored correctly may outperform a refrigerated product that spent two days in a hot delivery vehicle. Consumers should be counseled to:

1. Follow the storage instruction on the package exactly; do not assume refrigeration is always better or always necessary.
2. Check the expiration date and choose the longest available interval.
3. Avoid storing probiotics above the refrigerator or near stoves and windows.
4. Inspect capsules for discoloration, clumping, or odor before use.

For pharmacy teams, refrigerator placement matters. A probiotic stored next to a frost-free freezer door may experience repeated temperature swings that undermine the very stability the refrigerator was meant to provide.

A Practical Checklist for the Counter

When a customer asks for a recommendation, these questions separate meaningful labels from marketing:

• Is the CFU count guaranteed through the expiration date?
• Are strains identified to the strain level, and is at least one supported by published human data?
• Is the storage condition specified, and can the pharmacy verify it has been maintained?
• Does the product carry third-party verification, such as USP or NSF certification?
• Is the dosage form appropriate for the intended use?
• Has the customer's clinician been informed, particularly if the customer is immunocompromised or has a central venous catheter?

The last point is not a formality. Probiotic products are not risk-free. The FDA has issued warnings about the use of certain probiotic products in critically ill and immunocompromised patients, in whom live organisms have been associated with invasive infection. In those populations, the question is not whether the count is high enough but whether the product should be used at all.

The Bottom Line

A probiotic label is a starting point for inquiry, not a conclusion. The number on the front tells you what the manufacturer measured once; it does not tell you what is alive in the bottle today, what survives the stomach, or what evidence supports the strain inside. Consumers who ask about expiry-date guarantees, strain identity, storage, and third-party testing will make better decisions than those who compare headline counts. Pharmacists and technicians who can answer those questions clearly are providing something the label cannot: an assessment grounded in how these products actually behave.